Gepirone Under Review for Major Depressive Disorder
Exxua (previously named Travivo) is a novel oral serotonin 1A receptor agonist.
Exxua (previously named Travivo) is a novel oral serotonin 1A receptor agonist.
Researchers sought to characterize real-world efficacy of repeated ketamine infusions for treatment-resistant bipolar depression assessing symptoms of depression, anxiety, suicidality, and functioning.
In a prospective, longitudinal study, researchers assessed the effect of demographics, pre-COVID-19 comorbidities, index COVID-19 hospitalization metrics, and life stressors on 6- and 12-month outcome metrics in adult patients post-COVID-19 hospitalization.
Patients with acute appendicitis between 2000 and 2020 were evaluated for complications on the basis of having a mental health diagnosis.
A pragmatic, parallel-group, randomized control trial was conducted between 2020 and 2021 to ascertain whether a lifestyle modification program had an effect on patients with treatment-resistance depression.
This Swedish population-based study has the largest sample size to date exploring these associations.
Can reducing RNT with psychological treatment approaches help improve youth depression and anxiety?
The approval was based on data from 2 trials in adults who met DSM-IV-TR or DSM-5 criteria for MDD and had an inadequate response to 1 to 3 courses of prior antidepressant therapy.
The designation is supported by data from 3 clinical studies.
The trial compared Spravato (esketamine nasal spray) to quetiapine extended-release, both in combination with a continuing SSRI or SNRI.